Skip to main content

  • Login
Asma grave: servizi per i professionisti della salute - The Next Breath | go to homepage
INFIAMMAZIONE DI TIPO 2
COMORBIDITÀ
INFORMAZIONI UTILI
SERVIZI PER IL MEDICO
  • SERVIZI PER IL MEDICO
  • Login
Cerca
Asma grave: servizi per i professionisti della salute - The Next Breath | go to homepage
Cerca
Asma grave: servizi per i professionisti della salute - The Next Breath | go to homepage
INFIAMMAZIONE DI TIPO 2
COMORBIDITÀ
INFORMAZIONI UTILI
SERVIZI PER IL MEDICO
  • SERVIZI PER IL MEDICO
  • Login
  • Login
  • Cerca
    • Asma grave: servizi per i professionisti della salute - The Next Breath
    • Login

    Login

    {* #signInForm *} {* signInEmailAddress *} {* currentPassword *}

    Hai dimenticato la password? Clicca qui

    Registrati

    {* /signInForm *}

    Bentornata anonymous

    Verifica e-mail richiesta

    Per completare la registrazione, controlla la tua casella di posta e clicca sul link per confermare l’indirizzo mail. Per maggiori informazioni puoi contattarci qui

    Inviata con successo!
    Invia nuovamente la verifica dell'e-mail

    Ha dimenticato la password

    Se hai dimenticato la password, inserisci il tuo indirizzo email. Riceverai un link via e-mail per creare una nuova password.

    {* #forgotPasswordForm *} {* signInEmailAddress *}
    {* /forgotPasswordForm *}

    Crea nuova password

    Abbiamo inviato un'e-mail con le istruzioni per creare una nuova password. La tua password esistente non è stata modificata.

    Ok

    Crea nuova password

    Questo indirizzo email è stato registrato con un account social. Abbiamo inviato un'e-mail con le istruzioni per creare una nuova password, che può essere utilizzata in aggiunta ai tuoi provider social collegati.
    Ok

    Cambia la password

    {* #changePasswordFormNoAuth *} {* newPassword *} {* newPasswordConfirm *}
    {* /changePasswordFormNoAuth *}

    Password cambiata

    La tua password è stata aggiornata con successo.

    Accedi

    Crea nuova password

    Non abbiamo riconosciuto il codice di reimpostazione della password. Inserisci la tua email qui sotto e ti invieremo un'altra email.

    {* #resetPasswordForm *} {* signInEmailAddress *}
    {* /resetPasswordForm *}

    Password cambiata

    La tua password è stata aggiornata con successo.

    Accedi

    Impossibile fare il log in

    Non siamo in grado di accedere in questo momento. Riprova più tardi o contatta l'assistenza clienti.

    HCP Verifica richiesta

    Attenzione! Certificazione dei dati in corso, a conclusione riceverai un’email di conferma e potrai accedere all’area a te dedicata. Per maggiori informazioni puoi contattarci qui

    Mappa del sito

    Condizioni di utilizzo

    Cookie Policy

    Privacy Policy

    Bibliografia

    Contatti

    Sanofi S.r.l. Socio Unico - Direzione e Coordinamento Sanofi (Francia)
    Sede legale: Viale Luigi Bodio, 37/b - 20158 Milano Cap. Soc. € 202.279.195,04 I.v.
    Reg. Imprese Milano /C.F./P. IVA 00832400154 - sanofi@pec.it
    ©2022 Sanofi S.r.l. - Direzione e Coordinamento Sanofi (Francia)
    Sito sviluppato per il territorio italiano

    Bibliografia

    INFIAMMAZIONE DI TIPO 2

    Fisiopatologia e prevalenza

    1. Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016;15(1):35-50.
    2. Robinson D et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161-175.
    3. Global Initiative for Asthma. Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients. v2.0 April 2019, Pocket Guide.
    4. Peters MC et al. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014 Feb;133(2):388-94.
    5. Gauthier M et al. Am J Respir Crit Care Med. 2015 Sep 15;192(6):660-8.
    6. Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015 Sep 12;386(9998):1086-96.
    7. Fahy JV. Nat Rev Immunol. 2015 Jan;15(1):57-65.

    Meccanismi molecolari

    1. Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016;15(1):35-50.
    2. Robinson D et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161-175.
    3. Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015 Sep 12;386(9998):1086-96.
    4. Junttila IS. Tuning the Cytokine Responses: An Update on interleukin (iL)-4 and iL-13 Receptor Complexes. Front Immunol. 2018 Jun 7;9:888.
    5. Israel E & Reddel HK. Severe and Difficult-to-Treat Asthma in Adults. N Engl J Med. 2017 Sep 7;377(10):965-976.
    6. Shinkai A et. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol. 1999 Aug 1;163(3):1602-10.
    7. Steinke JW & Borish L. Th2 cytokines and asthma Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists Respir Res. 2001;2(2):66-70.

    Marker infiammazione di tipo 2

    1. Parulekar AD et al. Role of T2 inflammation biomarkers in severe asthma. Curr Opin Pulm Med. 2016 Jan;22(1):59-68.
    2. Katial RK et al. Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. J Allergy Clin Immunol Pract. 2017 Mar - Apr;5(2S):S1-S14.
    3. Prado CM et al. Nitric Oxide in Asthma Physiopathology. ISRN Allergy. 2011 Apr 19;2011:832560.
    4. Guzik TJ et al. Nitric Oxide and Superoxide in Inflammation and Immune Regulation. J Physiol Pharmacol. 2003 Dec;54(4):469-87.
    5. Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016;15(1):35-50.
    6. Rosenberg HF et al. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007 Jun;119(6):1303-10.
    7. de Vries IJ et al. Adhesion molecule expression on skin endothelia in atopic dermatitis: Effects of TNF-a and IL-4 J Allergy Clin Immunol. 1998 Sep;102(3):461-8.
    8. Shinkai A et. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol. 1999 Aug 1;163(3):1602-10.
    9. Global Initiative for Asthma. Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients. v2.0 April 2019, Pocket Guide.

    Cascata infiammatoria

    1. Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016;15(1):35-50.
    2. McGregor MC et al. Role of Biologics in Asthma. Am J Respir Crit Care Med. 2019 Feb 15;199(4):433-445.

    COMORBIDITÀ

    Comorbidità di tipo 2

    1. Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease Nat Rev Drug Discov 2016;15(1):35-50.
    2. Carr S and Watson W. Eosinophilic esophagitis. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):S8.

    Rinosinusite cronica con poliposi nasale

    1. Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int. 2015 Apr;64(2):121-30.
    2. Schleimer RP. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. Annu Rev Pathol. 2017;12:331-357.
    3. Ceylan E et al. Nasal polyps and the severity of asthma. Respirology. 2007 Mar;12(2):272-6.
    4. Chaaban MR et al. Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy 2013;27(6):473-478.
    5. Hulse KE et al. Pathogenesis of nasal polyposis. Clin Exp Allergy. 2015 Feb;45(2):328-46.
    6. Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015 Sep 12;386(9998):1086-96.
    7. Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease Nat Rev Drug Discov 2016;15(1):35-50.
    8. Dietz de Loos DA, et al. Symptoms in chronic rhinosinusitis with and without nasal polyps. Laryngoscope. 2013 Jan;123(1):57-63.
    9. Yamada T et al. Eotaxin-3 as a Plasma Biomarker for Mucosal Eosinophil Infiltration in Chronic Rhinosinusitis. Front Immunol. 2019 Feb 4;10:74.
    10. Robinson D et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017 Feb;47(2):161-175.
    11. Corren J et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020 Feb;8(2):516-526.
    12. McGregor MC et al. Role of Biologics in Asthma. Am J Respir Crit Care Med. 2019 Feb 15;199(4):433-445.
    13. Takabayashi T et al. Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression. Am J Respir Crit Care Med. 2013 Jan 1;187(1):49-57.
    14. Stevens WW et al. Chronic rhinosinusitis with nasal polyps. J Allergy Clin lmmunol Pract 2016;4(4):565-572.
    15. Akdis CA et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin lmmunol 2013;131(6):1479-1490.
    16. Khan A et al. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32-42.
    17. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy 2016;9:45-53.
    18. Bachert C et al. ICON: chronic rhinosinusitis. World Allergy Organ J 2014;7(1):25.
    19. Head K et al. Short-course oral steroids alone for chronic rhinosinusitis. Cochrane Database Syst Rev 2016;4:CD011991.
    20. Fokkens WJ et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl 2012;50(23):1-298.
    21. Vaidyanathan S et al. Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids. Ann Intern Med 2011;154(5):293-302.
    22. Van Zele T et al. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy 2014;28(3):192-198.
    23. Stevens WW et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin lmmunol Pract 2017;5(4):1061-1070. 8.
    24. De Greve G et al. Endotype‑driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017 Jul 12;7:22.
    25. xAIFA - Farmaci biologici. Da: https://www.aifa.gov.it/farmaci-biologici [Ultimo accesso: settembre 2020].x
    26. ISS - Farmaco chimico. Da: https://www.iss.it/farmaco-chimico. [Ultimo accesso: settembre 2020].
    27. EMA - Medicinali biosimilari nell'UE - Guida informativa per gli operatori sanitari. Da: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_it.pdf [Ultimo accesso: settembre 2020].
    28. Foltz IN et al. Evolution and Emergence of Therapeutic Monoclonal Antibodies. Circulation. 2013 Jun 4;127(22):2222-30.
    29. Fokkens WJ et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464.

    Dermatite atopica

    1. Gelmetti C et al. Dermatite atopica 2016-2017. Sidemast.
    2. Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease Nat Rev Drug Discov 2016;15(1):35-50.
    3. Heffler E et al. The Severe Asthma Network in Italy: Findings and Perspectives. J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1462-1468.
    4. Prescott JD et al. In Atopic Dermatitis, Looks Can Be Deceiving. Am J Manag Care 2016 (Suppl).

    Stai abbandonando il Sito

    Ti informiamo che quanto contenuto nel nuovo sito prescelto non è responsabilità di Sanofi Italia.

    Continua